期刊文献+

肺纤维化大鼠血清白细胞介素-4和表面活性蛋白-A动态变化及早期诊断意义 被引量:2

LEVELS OF SERUM INTERLEUKIN-4 AND SURFACTANT PROTEIN-A IN R ATS WITH PULMONARY FIBROSIS AND THEIR VALUE IN EARLY DIAGNOSIS
暂未订购
导出
摘要 目的探讨白细胞介素-4(interleukin 4,IL-4)和表面活性蛋白A(surfactant protein-A,SP-A)在肺纤维化大鼠中的表达水平及早期诊断意义。方法选取60只Wistar大鼠随机分为正常对照组、博莱霉素致肺纤维化模型组,每组30只,分别于造模后1、3、7、14、28天处死大鼠。应用酶联免疫吸附法(enzyme-linked immunosorbentassay,ELISA)及Western blot测定不同时相点血清IL-4、SP-A水平。结果模型组血清IL-4早期较对照组显著升高(P<0.01),血清SP-A各时相均高于对照组(P<0.05),并随病情进展而逐渐升高。结论血清IL-4、SP-A可作为诊断肺纤维化早期肺泡炎的灵敏指标,SP-A可反映肺纤维化严重程度。 Objective To detect the levels of serum interleukin-4 (IL-4) and surfactant protein-A (SP-A) in rats with pulmonary fibrosis that were induced by bleomycin and to evaluate their significance in early diagnosis of pulmonary fibrosis. Methods Sixty rats were randomly divided into two groups, control group and pulmonary fibrotic group, with 30 rats in each group. The rats were killed in turn at 1, 3, 7, 14 and 28 day. Enzyme-linked immunosorbent assay (ELISA) and Western blot were used to detect the levels of serum IL-4 and SP-A. Results The levels of serum IL-4 of the pulmonary fibrotic group were significantly higher than those of the control group at early stage (P〈0.01), while the levels of SP-A of the former group were always higher (P〈0.05). and tended to increase with the development of the disease. Conclusion Serum IL-4 and SP-A may be sensitive indicators in diagnosing early stage pulmonary fibrosis and SP-A reflects the development stages of the disease.
出处 《河北医科大学学报》 CAS 2005年第5期337-339,374,共4页 Journal of Hebei Medical University
关键词 肺纤维化 白细胞介素4 膜蛋白质类 大鼠 pulmonary fibrosis interleukin 4 membrane proteins rats
  • 相关文献

参考文献8

  • 1Hiroki T, Yoshio K, Hiroshi T, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis[J]. Am J Respir Crit Care Med, 2000, 162(1):258-263.
  • 2Barbarin V, Xing Z, Delos M, et al. Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles[J]. Am J Physiol Lung Cell Mol Physiol,2005,288(5):L841-848.
  • 3高晓方,崔社怀.特发性肺纤维化的抗纤维化治疗研究进展[J].中华结核和呼吸杂志,2004,27(6):366-368. 被引量:27
  • 4Mehrnaz GK, Yasuhiro N. Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis[J]. Cytokine, 2001,15(8):138-147.
  • 5Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6[J]. J Immunol, 2004,173(5):3425-3431.
  • 6Suwabe A. Lung injury and serum makers[J]. Rinsho Byori, 2002,50(6):1061-1066.
  • 7Phelps DS, Umstead TM, Mejia M, et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis[J]. Chest, 2004,125(2):617-25.
  • 8Greene KE, King TE Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis[J]. Eur Respir J,2002,19(3):439-446.

二级参考文献22

  • 1Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med, 2001, 134: 136-151.
  • 2Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 2000, 24: 477-491.
  • 3Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase Ⅱ study. Am J Respir Crit Care Med, 1999, 159: 1061-1069.
  • 4King TE Jr . Treatment advances and failures in pulmonary fibrosis. European Respiratory Society (ERS) Annual Congress, 2002 Sep 18. Sweden:Stockholm, Available from: URL: http://www.ersnet.org/2/4/2-4.asp.
  • 5Erickelberg O, Pansky A, Koehler E, et al. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J, 2001, 15: 797-806.
  • 6King TE Jr. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med, 2000, 342: 974-975.
  • 7Noble P. Pathology and current treatment options of idiopathic pulmonary fibrosis. European Respiratory Society (ERS) Annual Congress, 2002 Sep 18. Sweden:Stockholm, Available from: URL: http://www.ersnet.org/2/4/2-4.asp.
  • 8Sciavolino PJ, Lee TH, Vilcek J. Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1. J Biol Chem, 1994, 269: 21627-21634.
  • 9Wang R, Ibarra S, Verlinshi L, et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol, 2000, 279: L143-151.
  • 10Mason RJ, Schwarz MI, Hunninghake GW, et al. NHLBI workshop summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am J Respir Crit Care Med, 1999, 160: 1771-1777.

共引文献26

同被引文献44

  • 1王宁,沈国顺,白红光.白细胞介素4的研究进展[J].畜牧兽医科技信息,2006,22(1):23-25. 被引量:8
  • 2Zuber JP, Spertini F. Immunological basis of systemic scierosis. Rheumatology(Oxford), 2006, 45 (supol 3): iii23-25.
  • 3Kasaian MT, Miller DK. IL-13 as a therapeutic target for respira- tory disease. Biochem Pharmacol, 2008, 76: 147-155.
  • 4Becklake MR. The mineral dust diseases. Tuber Lung Dis, 1992, 73: 13-20.
  • 5Kips JC, Toumoy KG, Pauwels RA. New anti-asthma therapies: suppression ofthe effect of interleukin(IL)-4 and IL-5. Eur RespirJ, 2001, 17: 499-506.
  • 6Chen Y, Chen J, Dong J,et al. Antifibrotic effect of interferon gamma in silicosis model of rat. Toxicol Lett, 2005, 155: 353-360.
  • 7Rook GA, Hernandez-Pando R, Dheda K, et al. IL-4 in tuberculo- sis: implications for vaccine design. Trends Immunol, 2004, 25: 483-488.
  • 8Asadullah K, Sterry W, Trefzer U. Cytokines: interleukin and in- terferon therapy in dermatology. Clin Exp Dermatol, 2002, 27: 578-584.
  • 9Gyan BA, Goka B, Cvetkovic JT, et al. Allelic polymorphisms in the repeat and promoter regions of the interleukin-4 gene and malaria severity in Ghanaian children. Clin Exp Immunol, 2004, 138: 145-150.
  • 10Donfack J, Schneider DH, Tan Z, et al. Variation in conserved non-coding sequences on chromosome 5q and susceptibility to asthma and atoov. Respir Res, 2005, 6: 145-156.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部